These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 24843064)

  • 1. Timely versus delayed early childhood vaccination and seizures.
    Hambidge SJ; Newcomer SR; Narwaney KJ; Glanz JM; Daley MF; Xu S; Shoup JA; Rowhani-Rahbar A; Klein NP; Lee GM; Nelson JC; Lugg M; Naleway AL; Nordin JD; Weintraub E; DeStefano F
    Pediatrics; 2014 Jun; 133(6):e1492-9. PubMed ID: 24843064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of measles-containing vaccines in 1-year-old children.
    Klein NP; Lewis E; Fireman B; Hambidge SJ; Naleway A; Nelson JC; Belongia EA; Yih WK; Nordin JD; Hechter RC; Weintraub E; Baxter R
    Pediatrics; 2015 Feb; 135(2):e321-9. PubMed ID: 25560438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia.
    Macartney K; Gidding HF; Trinh L; Wang H; Dey A; Hull B; Orr K; McRae J; Richmond P; Gold M; Crawford N; Kynaston JA; McIntyre P; Wood N;
    JAMA Pediatr; 2017 Oct; 171(10):992-998. PubMed ID: 28806450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
    Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P
    Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similar relative risks of seizures following measles containing vaccination in children born preterm compared to full-term without previous seizures or seizure-related disorders.
    McClure DL; Jacobsen SJ; Klein NP; Naleway AL; Kharbanda EO; Glanz JM; Jackson LA; Weintraub ES; McLean HQ
    Vaccine; 2019 Jan; 37(1):76-79. PubMed ID: 30478005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P; Lim FS; Han HH; Willems P
    Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of the use of MMRV in infants by pediatric infectious disease specialists with that of other affiliated providers.
    Ackerson BK; Li BH; Sy LS; Cheetham TC; Jacobsen SJ
    Vaccine; 2014 Apr; 32(16):1863-8. PubMed ID: 24508041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measles-containing vaccines and febrile seizures in children age 4 to 6 years.
    Klein NP; Lewis E; Baxter R; Weintraub E; Glanz J; Naleway A; Jackson LA; Nordin J; Lieu T; Belongia EA; Fireman B
    Pediatrics; 2012 May; 129(5):809-14. PubMed ID: 22473362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
    Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Policy statement—Prevention of varicella: update of recommendations for use of quadrivalent and monovalent varicella vaccines in children.
    Committee on Infectious Diseases
    Pediatrics; 2011 Sep; 128(3):630-2. PubMed ID: 21873692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination.
    Schink T; Holstiege J; Kowalzik F; Zepp F; Garbe E
    Vaccine; 2014 Feb; 32(6):645-50. PubMed ID: 24374498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Febrile seizures following measles and varicella vaccines in young children in Australia.
    Macartney KK; Gidding HF; Trinh L; Wang H; McRae J; Crawford N; Gold M; Kynaston A; Blyth C; Yvonne Z; Elliott E; Booy R; Buttery J; Marshall H; Nissen M; Richmond P; McInytre PB; Wood N;
    Vaccine; 2015 Mar; 33(11):1412-7. PubMed ID: 25444797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine.
    ;
    MMWR Morb Mortal Wkly Rep; 2008 Mar; 57(10):258-60. PubMed ID: 18340332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine.
    LeBaron CW; Bi D; Sullivan BJ; Beck C; Gargiullo P
    Pediatrics; 2006 Oct; 118(4):1422-30. PubMed ID: 17015532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures.
    Klein NP; Fireman B; Yih WK; Lewis E; Kulldorff M; Ray P; Baxter R; Hambidge S; Nordin J; Naleway A; Belongia EA; Lieu T; Baggs J; Weintraub E;
    Pediatrics; 2010 Jul; 126(1):e1-8. PubMed ID: 20587679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of age on the risk of Fever and seizures following immunization with measles-containing vaccines in children.
    Rowhani-Rahbar A; Fireman B; Lewis E; Nordin J; Naleway A; Jacobsen SJ; Jackson LA; Tse A; Belongia EA; Hambidge SJ; Weintraub E; Baxter R; Klein NP
    JAMA Pediatr; 2013 Dec; 167(12):1111-7. PubMed ID: 24126936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
    Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
    Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children.
    France EK; Glanz J; Xu S; Hambidge S; Yamasaki K; Black SB; Marcy M; Mullooly JP; Jackson LA; Nordin J; Belongia EA; Hohman K; Chen RT; Davis R;
    Pediatrics; 2008 Mar; 121(3):e687-92. PubMed ID: 18310189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.